Neurodegenerative disorders treatment: The microRNA role

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease and prion disease are not timely and effectively treated using conventional therapies. This emphasizes the need for alternative therapeutic approaches. In this respect, gene-based therapies have been adopted as potentially feasible alternative therapies, where the microRNA (miRNA) approach has experienced a great explosion in recent years. Because miRNAs have been shown to be implicated in the pathogenesis of several diseases including neurodegenerative diseases, they are intensely studied as candidates for diagnostic and prognostic biomarkers, as predictors of drug response and as therapeutic agents. In this review, we evaluate the feasibility of both direct and indirect miRNA mimics and inhibitors toward the regulation of neurodegenerative-related genes both in vivo and in vitro models, highlight the advantages and drawbacks associated with miRNA-based therapy, and summarize the relevant techniques and approaches attempted to deliver miRNAs to the central nervous system for therapeutic purposes, with particular regard to the exosomes. Additionally, we describe a new approach that holds great promise for the treatment of a wide range of diseases including neurodegenerative disorders. This approach is based on addressing the incorporation of miRNAs into exosomes to increase the quantity and quality of miRNA packed and delivered to the central nervous system and other sites of action.

Original languageEnglish
Pages (from-to)327-363
Number of pages37
JournalCurrent Gene Therapy
Volume17
Issue number5
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

MicroRNAs
Neurodegenerative Diseases
Exosomes
Therapeutics
Central Nervous System
Prion Diseases
Explosions
Huntington Disease
Amyotrophic Lateral Sclerosis
Complementary Therapies
Genetic Therapy
Parkinson Disease
Alzheimer Disease
Biomarkers
Pharmaceutical Preparations
Genes

Keywords

  • Exosomes
  • MicroRNA
  • MiRNA delivery
  • MiRNA inhibitors
  • MiRNA mimics
  • MiRNA-based therapy
  • Neurodegenerative diseases
  • Therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Drug Discovery
  • Genetics(clinical)

Cite this

Neurodegenerative disorders treatment : The microRNA role. / Ridolfi, Barbara; Abdel-Haq, Hanin.

In: Current Gene Therapy, Vol. 17, No. 5, 01.10.2017, p. 327-363.

Research output: Contribution to journalReview article

@article{0c00f5cdd2b640c9aa56ba3339ef3dfe,
title = "Neurodegenerative disorders treatment: The microRNA role",
abstract = "Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease and prion disease are not timely and effectively treated using conventional therapies. This emphasizes the need for alternative therapeutic approaches. In this respect, gene-based therapies have been adopted as potentially feasible alternative therapies, where the microRNA (miRNA) approach has experienced a great explosion in recent years. Because miRNAs have been shown to be implicated in the pathogenesis of several diseases including neurodegenerative diseases, they are intensely studied as candidates for diagnostic and prognostic biomarkers, as predictors of drug response and as therapeutic agents. In this review, we evaluate the feasibility of both direct and indirect miRNA mimics and inhibitors toward the regulation of neurodegenerative-related genes both in vivo and in vitro models, highlight the advantages and drawbacks associated with miRNA-based therapy, and summarize the relevant techniques and approaches attempted to deliver miRNAs to the central nervous system for therapeutic purposes, with particular regard to the exosomes. Additionally, we describe a new approach that holds great promise for the treatment of a wide range of diseases including neurodegenerative disorders. This approach is based on addressing the incorporation of miRNAs into exosomes to increase the quantity and quality of miRNA packed and delivered to the central nervous system and other sites of action.",
keywords = "Exosomes, MicroRNA, MiRNA delivery, MiRNA inhibitors, MiRNA mimics, MiRNA-based therapy, Neurodegenerative diseases, Therapy",
author = "Barbara Ridolfi and Hanin Abdel-Haq",
year = "2017",
month = "10",
day = "1",
doi = "10.2174/1566523218666180119120726",
language = "English",
volume = "17",
pages = "327--363",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Neurodegenerative disorders treatment

T2 - The microRNA role

AU - Ridolfi, Barbara

AU - Abdel-Haq, Hanin

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease and prion disease are not timely and effectively treated using conventional therapies. This emphasizes the need for alternative therapeutic approaches. In this respect, gene-based therapies have been adopted as potentially feasible alternative therapies, where the microRNA (miRNA) approach has experienced a great explosion in recent years. Because miRNAs have been shown to be implicated in the pathogenesis of several diseases including neurodegenerative diseases, they are intensely studied as candidates for diagnostic and prognostic biomarkers, as predictors of drug response and as therapeutic agents. In this review, we evaluate the feasibility of both direct and indirect miRNA mimics and inhibitors toward the regulation of neurodegenerative-related genes both in vivo and in vitro models, highlight the advantages and drawbacks associated with miRNA-based therapy, and summarize the relevant techniques and approaches attempted to deliver miRNAs to the central nervous system for therapeutic purposes, with particular regard to the exosomes. Additionally, we describe a new approach that holds great promise for the treatment of a wide range of diseases including neurodegenerative disorders. This approach is based on addressing the incorporation of miRNAs into exosomes to increase the quantity and quality of miRNA packed and delivered to the central nervous system and other sites of action.

AB - Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease and prion disease are not timely and effectively treated using conventional therapies. This emphasizes the need for alternative therapeutic approaches. In this respect, gene-based therapies have been adopted as potentially feasible alternative therapies, where the microRNA (miRNA) approach has experienced a great explosion in recent years. Because miRNAs have been shown to be implicated in the pathogenesis of several diseases including neurodegenerative diseases, they are intensely studied as candidates for diagnostic and prognostic biomarkers, as predictors of drug response and as therapeutic agents. In this review, we evaluate the feasibility of both direct and indirect miRNA mimics and inhibitors toward the regulation of neurodegenerative-related genes both in vivo and in vitro models, highlight the advantages and drawbacks associated with miRNA-based therapy, and summarize the relevant techniques and approaches attempted to deliver miRNAs to the central nervous system for therapeutic purposes, with particular regard to the exosomes. Additionally, we describe a new approach that holds great promise for the treatment of a wide range of diseases including neurodegenerative disorders. This approach is based on addressing the incorporation of miRNAs into exosomes to increase the quantity and quality of miRNA packed and delivered to the central nervous system and other sites of action.

KW - Exosomes

KW - MicroRNA

KW - MiRNA delivery

KW - MiRNA inhibitors

KW - MiRNA mimics

KW - MiRNA-based therapy

KW - Neurodegenerative diseases

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85043315330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043315330&partnerID=8YFLogxK

U2 - 10.2174/1566523218666180119120726

DO - 10.2174/1566523218666180119120726

M3 - Review article

AN - SCOPUS:85043315330

VL - 17

SP - 327

EP - 363

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 5

ER -